保乳术联合新辅助化疗治疗乳腺癌的临床效果观察  

Clinical Effect of Breast Conserving Surgery Combined with Neoadjuvant Chemotherapy in the Treatment of Breast Cancer

作　　者：赵丰 魏德强[1] ZHAO Feng;WEI Deqiang(Jian’ou Municipal Hospital,Jian’ou 353100,China;不详)

机构地区：[1]建瓯市立医院,福建建瓯353100

出　　处：《中外医学研究》2023年第23期119-122,共4页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：目的:观察保乳术联合新辅助化疗治疗乳腺癌的临床效果。方法:选取2021年9月-2022年9月建瓯市立医院收治的80例乳腺癌患者为研究对象,经抽签法,按1∶1比例将其分为观察组和对照组,各40例,两组患者均接受保乳术治疗,观察组予以新辅助化疗配合治疗,比较两组治疗后的血清肿瘤标志物水平、治疗效果、免疫功能及生命质量。结果:治疗后,观察组的糖类抗原15-3(CA15-3)、糖类抗原125(CA125)、癌胚抗原(CEA)、甲胎蛋白(AFP)水平均低于对照组,差异有统计学意义(P<0.05)。观察组治疗总有效率为82.50%(33/40),高于对照组的67.50%(27/40),差异有统计学意义(P<0.05)。治疗后,两组免疫球蛋白G(IgG)、免疫球蛋白M(IgM)、T淋巴细胞亚群CD4+、CD3+等免疫功能指标水平均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05)。治疗后,两组乳腺癌治疗功能评估量表(FACT-B)评分高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05)。结论:保乳术联合新辅助化疗可有效控制乳腺癌患者肿瘤标志物水平,可在增强患者疗效的同时改善机体免疫功能,对提升术后生命质量有积极意义。Objective:To observe the clinical effect of breast conserving surgery combined with neoadjuvant chemotherapy in the treatment of breast cancer.Method:Eighty patients with breast cancer admitted to Jian’ou Municipal Hospital from September 2021 to September 2022 were selected as the research objects.They were divided into the observation group and the control group according to the ratio of 1∶1 by drawing lots,with 40 patients in each group.The patients in both groups received breast conserving surgery.The observation group received neoadjuvant chemotherapy combination with treatment.The serum tumor marker levels,treatment effects,immune function and quality of life of the two groups after treatment were compared.Result:After treatment,the levels of carbohydrate antigen 15-3(CA15-3),carbohydrate antigen 125(CA125),carcinoembryonic antigen(CEA)and alpha-fetoprotein(AFP)in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).The total effective rate of the observation group was 82.50%(33/40),which was higher than 67.50%(27/40)of the control group,the difference was statistically significant(P<0.05).After treatment,the immune function indexes such as immunoglobulin G(IgG),immunoglobulin M(IgM),T lymphocyte subsets CD4+,CD3+in both group were higher than those before treatment,and the observation group were higher than those in the control group,the differences were statistically significant(P<0.05).After treatment,the functional assessment of cancer therapybreast(FACT-B)score both group were higher than those before treatment,and the observation group was higher than that of the control group,the differences were statistically significant(P<0.05).Conclusion:The breast conserving surgery combined with neoadjuvant chemotherapy for breast cancer patients can effectively control the level of tumor markers,enhance the efficacy of patients and improve the immune function of the body,which has positive significance in improving the quality of life after

关 键 词：乳腺癌 保乳术 新辅助化疗 免疫功能 肿瘤标志物 生活质量 

分 类 号：R737.9[医药卫生—肿瘤]